Optimizing cell proliferation and function for immunotherapy with recombinant growth factors & cytokines

As more and new immune cell therapies continue to be developed, the demand for Animal Component-Free (ACF) and GMP-quality recombinant human growth factors and cytokines has increased. Cytokine therapies have become extremely popular due to their effectiveness in the treatment of cancer and autoimmune conditions. The use of GMP products is the gold standard for Cell & Gene therapy manufacturing. Especially the use of GMP recombinant human interleukins as companies prepare for clinical trials or scale-up manufacturing of their immune cell therapies.

Interleukins (ILs) are a group of cytokines that regulate immune and inflammatory responses. Interleukins also regulate cell growth, differentiation, and motility. The discovery of Interleukin (IL-2) as a “T-cell growth factor” (TCGF) in 1976 revolutionized the fields of basic immunology research and immunotherapy for human cancers.

FUJIFILM Irvine Scientific and Shenandoah Biotechnology, have joined forces to provide Cell & Gene therapy manufacturers with a portfolio of animal component-free recombinant proteins, a single point of access to accelerate life science research, discovery, for cell and gene therapy development.

CTGrade Recombinant Human Interleukins, are designed to optimize cell expansion, activation, proliferation, and differentiation while providing consistent lot-to-lot biological activity and performance. In order to achieve success and ensure predictable workflow performance in the proliferation and differentiation of T cells, natural killer (NK) cells, B cells, and chimeric antigen receptor (CAR-T) cells, these animal component-free (ACF) human recombinant growth factors, are produced in E. coli, and other sources, and are manufactured under strict cGMP guidelines.

Learn more about optimizing cell proliferation and function for immunotherapy.

• Interleukins (ILs): The role they play in the regulation of adaptive cellular response
• Developing recombinant growth factors and cytokines for cell-based therapies
• Achieving optimal results through scientifically driven selection of products
• Importance of a raw material supplier with a strong Quality system

  
  

Martin P Keough PhD

Shenandoah Biotechnologies Inc, a FUJIFILM Irvine Scientific company

Martin P. Keough joins FUJIFILM Irvine Scientific as Chief Scientific Officer for Shenandoah Biotechnology, Inc., bringing over 27 years of experience in biological research, specifically focused in the fields of molecular biology, cell biology, and immunology. Prior to joining Shenandoah Biotechnology, Inc., Dr. Keough’s research areas of interest included studies of the tumor microenvironment, gene therapy, development of molecular-based immunoassays for the detection of food-borne pathogens, and CAR T cell research. Dr. Keough holds a Bachelor of Biology from Villanova University and a Doctor of Philosophy in Biomedical Science from the University of Connecticut.